In the treatment of psoriasis, preliminary evidence supports the hypothesis that IL-23 inhibitors are capable of extended remissions and protection against PsA relative to other biologics.

The researchers highlighted that psoriasis is a systemic condition linked to various comorbidities, emphasizing the ...

Adults taking the novel once-daily oral pill for plaque psoriasis have significantly higher rates of clear or almost clear ...

Two-thirds of patients with moderate or severe plaque psoriasis had complete or nearly complete clearance at 4 months with an ...

Protagonist Therapeutics broke out Monday after the company's drug topped its rival from Bristol in a psoriasis study.

Adults and adolescents treated with icotrokinra experienced improvements in their moderate to severe plaque psoriasis, ...

Johnson & Johnson’s once-daily oral peptide has bested Bristol Myers Squibb’s reigning oral psoriasis med Sotyktu in a ...

Tildrakizumab showed early and sustained effectiveness and quality of life (QOL) improvements in patients with moderate to ...

Late-stage data also showed that Johnson & Johnson’s icotrokinra was superior to Bristol Myers Squibb’s Sotyktu at clearing ...

J&J's head of immunodermatology Liza O'Dowd said that the "robust results" with its oral IL-23 drug have the potential to ...